Kikuchi-Fujimoto Disease Following COVID-19 Infection in a 7-Year-Old Girl: A Case Report and Literature Review

Yusuke Saito 1, Yuta Suwa 1, Yakuto Kaneko 2, Mitsuhiro Tsujiwaki 3, Yasuhisa Odagawa 1
1. Pediatrics, Otaru General Hospital, Otaru, JPN
2. Otolaryngology, Otaru General Hospital, Otaru, JPN
3. Clinical Pathology, Otaru General Hospital, Otaru, JPN

Corresponding author: Yusuke Saito, ysaitoh0256@gmail.com

Abstract

The coronavirus disease 2019 (COVID-19) symptoms in children are relatively mild and often do not require treatment. Nonetheless, complications caused by the immune response to COVID-19 in children are possible and diverse. We present the case of a 7-year-old girl with persistent fever and lymphadenopathy arising from SARS-CoV-2 infection, diagnosed with Kikuchi-Fujimoto Disease (KFD) on lymph node biopsy. KFD is a rare benign disease, clinically characterized by fever and tender cervical lymphadenopathy affecting posterior cervical lymph nodes. We also reviewed six previously reported cases of COVID-19-associated KFD that occurred in school-aged children and compared them with the present case. The clinical course of COVID-19-associated KFD was similar to that of previous reports of KFD with a favorable prognosis. This is the first report of a school-aged child developing KFD following SARS-CoV-2 infection. KFD should be considered when approaching patients with hyperinflammatory states who present with prolonged fever and cervical lymphadenopathy after COVID-19.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still widespread. Its symptoms in children are relatively mild, without the need of treatment in many cases [1]. However, complications caused by the immune response following COVID-19 in children and neonates are diverse [2]. At present, COVID-19 is a disease that have the potential to lead to the most devastating sequelae as a result of an induced hyperinflammatory state. There are reported cases of multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease following COVID-19 infection in children [3,4]. Kikuchi-Fujimoto disease (KFD) or histiocytic necrotizing lymphadenitis, is a rare, generally self-limiting condition of unknown cause, usually characterized by cervical lymphadenopathy, fever, and leukopenia [5,6]. While the pathogenesis of KFD is unknown, the clinical presentation, course, and histologic changes suggest an immune response of T cells and histiocytes to an infectious agent. Infectious agents, including Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, human T-lymphotropic virus type 1, rhinovirus, and parvovirus B19 were proposed to be predisposing factors for KFD [7]. In addition, a few cases of KFD after COVID-19 have been reported in adolescents and adults. We encountered a school-aged patient, who presented with fever and lymphadenopathy following SARS-CoV-2 infection that turned out to be KFD.

Case Presentation

A previously healthy 7-year-old Japanese girl was admitted to our hospital with an 8-day history of fever and cervical lymphadenopathy following a SARS-CoV-2 infection. The patient had no history of respiratory symptoms. She was fully vaccinated and did not have any type of allergy. There was no recent history of travel, and contact with animals. She was initially diagnosed with lymphadenitis and treated with oral antibiotics (cefpodoxime proxetil) for three days and intravenous antibiotics (ampicillin-sulbactam) for three more days with no improvement. The complete blood count showed the following results: white cell count: 4.1 × 10^3 cells/μL; absolute lymphocyte count: 2.1 × 10^3 cells/μL; absolute neutrophil count: 1.7 × 10^3 cells/μL; platelets: 212 × 10^3 cells/μL; and hemoglobin: 11.6 g/dL. The following biochemistries were also observed: D-dimer level: 1.4 mg/L; lactate dehydrogenase: 291 U/L; aspartate aminotransferase: 21 U/L; alanine aminotransferase: 11 U/L; triglyceride: 130 mg/dL; C-reactive protein: 3.1 mg/dL; serum procalcitonin: 0.12 ng/mL; ferritin: 160 ng/mL with negative antinuclear antibody. Finally, the cytomegalovirus and Epstein-Barr virus serology tests were compatible with past infections (Table 1).
| Laboratory                        | Result          | Reference range          |
|----------------------------------|-----------------|--------------------------|
| Complete blood count             |                 |                          |
| White blood cells                | 4.1 x 10^3/μL   | 3.3-8.6 (x 10^3/μL)     |
| Neutrophil count                 | 1.7 x 10^3/μL   | -                        |
| Lymphocyte count                 | 2.1 x 10^3/μL   | -                        |
| Hemoglobin                       | 11.6 g/dL       | 11.6-14.0 g/dL           |
| Platelets                        | 212 x 10^3/μL   | 158-348 x 10^3/μL        |
| **Biochemistries**               |                 |                          |
| Lactate dehydrogenase            | 291 U/L         | 124-222 U/L              |
| Aspartate aminotransferase       | 21 U/L          | 13-33 U/L                |
| Alanine aminotransferase         | 11 U/L          | 7-23 U/L                 |
| Triglyceride                     | 130 mg/dL       | 30-117 mg/dL             |
| C-reactive protein               | 3.1 mg/dL       | 0.80-1.14 mg/dL          |
| Procalcitonin                    | 0.12 ng/mL      | 0.50-1.05 ng/mL          |
| Ferritin                         | 180.3 mg/mL     | 4.63-204 mg/mL           |
| Erythrocyte sedimentation rate   | 70 mm/hour      | 3-15 mm/hour             |
| Antinuclear antibodies           | <40             | <40                      |
| D-dimer                          | 1.4 μg/mL       | 0.5-1.01 μg/mL           |
| Human soluble interleukin 2 receptor | 641 μg/mL     | 157-474 μg/mL           |
| CD4                              | 28.80%          | 24.3-49.7%               |
| CD8                              | 32%             | 18.4-46%                 |
| CD4/8                            | 0.9             | 0.419                    |
| Cytomegalovirus IgM              | 0.13 Index      | <0.85 Index              |
| Cytomegalovirus IgG              | 161 AU/mL       | <6 AU/mL                 |
| Early antigen-diffuse IgG        | <10             | <10                      |
| Viral capsid antigen IgM         | <10             | <10                      |
| Viral capsid antigen IgG         | 40              | <10                      |
| Epstein-Barr nuclear antigen     | 40              | <10                      |

**TABLE 1: Laboratory investigations**

A computed tomography revealed five left cervical lymph nodes measuring approximately 25 × 20 mm without enlargement of lymph nodes in the axillary, mediastinum, or thoracic chains. The lymph nodes showed a focal low attenuation, and a central nodal necrotic change was suspected (Figure 1). The biopsy revealed a lymph node architecture with diffuse polymorphic lymphohistiocytic infiltrate with foci of necrosis (Figure 2A). Immunohistochemically, we observed positive staining for CD68 histiocytes (Figure 2B) admixed with CD3-positive T cells and CD20-positive B cells. Lymphoid malignancy was not detected. The flow cytometry results were negative for monotypic B and T cells. The patient tested negative for the COVID-19 rapid antigen test on day 11, with defervescence on day 15. The skin lesions appeared on day 18 and resolved on day 25.
FIGURE 1: Coronal and axial cuts of a contrast-enhanced computed tomography of the neck

Coronal and axial cuts of a contrast-enhanced computed tomography of the neck showing multiple enlarged and enhanced lymph nodes in the left cervical chain (arrows).

FIGURE 2: Histopathology of the lymph node biopsy specimens

(A) Hematoxylin & eosin (H&E) stain (100× magnification) showing zones of necrosis. Necrotizing lymphadenitis with Kikuchi-Fujimoto disease-like features (B) Histiocytes are CD68-positive. (100× magnification)

The lymphadenopathy also showed a tendency to shrink by day 28. Considering the course of the disease (fever, lymphadenopathy, and skin lesions), the results of the computed tomography, and histopathological examination of the lymph node, KFD was diagnosed and was attributed to a SARS-CoV-2 infection. Due to the spontaneous improvement of her general condition, normalization of laboratory tests, it was decided that no targeted treatment was necessary. The patient was discharged in good condition. Patients should be closely followed for recurrence.

Discussion

Pediatric COVID-19 infections are mild and often asymptomatic. There is a low risk of severe illness or death in children with COVID-19 [1]. The cervical lymphadenopathy and fever for more than seven days are atypical in pediatric COVID-19 patients and requires scrutiny of the cause to select effective treatment.

More recently, six cases of KFD were described after COVID-19, the main features of which are listed in Table 2[8-13]. This patient was the first school-aged child among the six reported cases of KFD after COVID-19 infection, with an age of onset ranging from 5 to 43 years. It has been reported that the duration of KFD onset after COVID-19 infection ranges from 1 to 3 months; however, only this patient had a fever that persisted after COVID-19. The clinical features, laboratory findings, and recurrence of KFD may differ according to age [14]. Fever, tender lymph nodes, and skin lesions are far more prevalent in children than in adults. Myalgia and weight loss were significantly higher in adults than in children [14]. COVID-19-related KFD showed the same clinical symptoms as those previously reported. This case had clinical symptoms typical of children compared to the previous five cases. A previous report showed that KFD patients...
presented with lymphadenopathy involving cervical, axillary, inguinal, and mesenteric nodes in 90.0%, 8.8%, 6.3%, and 2.5% of patients, respectively [14]. There was no difference in lymph node size between children and adults [14]. Cervical lymphadenopathy, often exceeding 2 cm in diameter, was noted in all cases. The clinical course of these cases was favorable, necessitating only symptomatic treatment to control fever.

| Author        | Gender | Age | The interval between the first symptom or lymphadenopathy and COVID-19 | Clinical presentation                                                                 | Site of LAD | LN maximum size (cm) | Treatment | Outcome         |
|---------------|--------|-----|-------------------------------------------------|--------------------------------------------------------------------------------------|------------|---------------------|-----------|------------------|
| Stimson et al. | M      | 17  | Unknown                                        | Lymphadenopathy, parotid gland enlargement, fever, weight loss, and fatigue          | Cervical   | 1.3                 | No data   | Complete resolution |
| Racette et al. | M      | 32  | 3 months                                       | Fever, chills, neck swelling, fatigue, myalgias                                    | Cervical   | No data             | Prednisone| Complete resolution |
| Jaseh et al.  | F      | 16  | Unknown                                        | Lymphadenopathy, fever, night sweats, myalgia, weight loss, erythematous plaques     | Cervical   | 2.5                 | Prednisone| Improvement       |
| Masiak et al. | M      | 43  | 5 weeks                                        | Lymphadenopathy, fever, skin lesions, hepatosplenomegaly, cardiac involvement        | Cervical   | 2.0                 | Antipyrin  | Complete resolution |
| Al Ghaideer et al. | M | 13  | 1 month                                        | Lymphadenopathy, fever, night sweats, weight loss, anorexia, abdominal pain        | Cervical   | 2.8                 | NSAIDs    | Complete resolution |
| Catch et al.  | M      | 5   | 5 weeks                                        | Lymphadenopathy, fever, sore throat                                              | Cervical   | 2.0-5.0             | No treatment| Complete resolution |
| Presented case | F      | 8   | Simultaneous                                   | Lymphadenopathy, fever, skin lesions                                             | Cervical   | 2.5                 | No treatment| Complete resolution |

TABLE 2: Main features of the cases of COVID-19-associated Kikuchi-Fujimoto disease

LAD: left anterior descending; LN: lymph node; NSAIDs: non-steroidal anti-inflammatory drugs

The most common hypotheses discussed in the literature are infectious and autoimmune conditions, which may manifest similarly. Several infectious agents were supposed to incite KFD including Epstein-Barr virus, human immunodeficiency virus, human herpesvirus 6, human T-lymphotropic virus type 1, and parvovirus B19. However, there is no evidence that infection may directly cause KFD, and several studies have failed to detect these infectious agents in the involved lymph nodes [7]. To investigate the association between KFD and COVID-19, an attempt was made to detect SARS-CoV-2 in lymphoid tissue in one case; however, the result was negative [9]. In addition, five cases of KFD after COVID-19 vaccination have been reported [15-18]. These reports suggest that the immunological mechanism induced by COVID-19 cause KFD.

With no other cause of KFD other than COVID-19 in the patient, the diagnosis was confirmed by CT findings and histopathological examination. The histopathological findings were characterized by necrosis and the presence of T lymphocytes, including CD68+ histiocytes, CD4+ and CD8+ T cells, in agreement with previous reports [19,20]. Although inflammation is presumed to be involved in the pathogenesis of KFD after COVID-19, further analysis is required. Therefore, KFD should be considered in children with prolonged fever and lymphadenopathy after COVID-19. Patients should be closely followed for recurrence.

Conclusions

We present the case of a 7-year-old girl with persistent fever and lymphadenopathy arising from SARS-CoV-2 infection, diagnosed with KFD on lymph node biopsy. The interval between the COVID-19 infection and KFD onset was at least one month in previous case reports, whereas the simultaneous existence of lymphadenopathy in this case clearly suggests that COVID-19 can be a direct cause of KFD. Pediatric COVID-19 infections are mild and often asymptomatic. However, KFD should be considered in children with prolonged fever and lymphadenopathy after COVID-19.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S: Epidemiology of COVID-19 among children in China. *Pediatrics.* 2020, 145:e20200702. 10.1542/peds.2020-0702
2. Satnarine T, Kin CML: COVID-19 exposure: a possible association with congenital anomalies and adverse neonatal outcomes. *JMBH.* 2022, 5:4-8. 10.32996/jmbhs.2022.5.2.8
3. Fernandes DM, Oliveira CR, Guerraia S, et al.: Severe acute respiratory syndrome coronavirus 2 clinical syndromes and predictors of disease severity in hospitalized children and youth. *J Pediatr.* 2021, 230:23-31.e10. 10.1016/j.jpeds.2020.11.016
4. Shekerdemian LS, Mahmood NR, Wolfe KK, et al.: Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatr.* 2020, 174:868-75. 10.1001/jamapediatrics.2020.1948
5. Fujimoto Y, Kojima Y, Yamaguchi K: Cervical subacute necrotizing lymphadenitis. A new clinicopathological entity. *Naika.* 1972, 20:920-7.
6. Perry AM, Choi SM: Kikuchi-Fujimoto Disease: a review. *Arch Pathol Lab Med.* 2018, 142:1341-6. 10.5858/arpa.2018-0219-RA
7. Bosch X, Guibert A, Miquel R, Campo E: Enigmatic Kikuchi-Fujimoto disease: a comprehensive review. *Am J Clin Pathol.* 2004, 122:141-52. 10.1309/YF081L4TKVYVYVPQ
8. Stimson L, Stitson R, Bahadi-Hardo M, Rennaudon-Smith E: COVID-19 associated Kikuchi-Fujimoto disease. *Br J Haematol.* 2021, 192:e124-6. 10.1111/bjhe.17292
9. Racette SD, Alexiev BA, Angarone MP, et al.: Kikuchi-Fujimoto disease presenting in a patient with SARS-CoV-2: a case report. *BMC Infect Dis.* 2021, 21:740. 10.1186/s12879-021-06048-0
10. Jaseb K, Nameh Gohuy Fard N, Rezaei N, Sadeghian S, Sadeghian S: COVID-19 in a case with Kikuchi-Fujimoto disease. *Clin Case Rep.* 2021, 9:1279-82. 10.1002/ccr3.3748
11. Maslak A, Lass A, Kowalski I, Haiduk A, Zdrojewski Z: Self-limiting COVID-19-associated Kikuchi-Fujimoto disease with heart involvement: case-based review. *Rheumatol Int.* 2022, 42:541-8. 10.1007/s00296-021-05085-8
12. Al Ghadeer HA, AlKadhem SM, AlMajed MS, AlAmer HM, AlHabeeb JA, Alomran SH, AlMajed AS: Kikuchi-Fujimoto disease following COVID-19. *Cureus.* 2022, 14:e21049. 10.7759/cureus.21049
13. Öztürk N, Kılıç İ, Göçün PU, Bayazıt: Kikuchi-Fujimoto disease in a child who had a high suspicion of COVID-19 infection. *J Hematopathol.* 2022, 1-2. 10.1007/s12308-022-00501-y
14. Kim HY, Jo HY, Kim SH: Clinical and laboratory characteristics of Kikuchi-Fujimoto disease according to age. *Front Pediatr.* 2021, 9:74506. 10.3389/fped.2021.74506
15. Souh HA, Ibrahim W, Maslaman MA, Ali G, Jumme W, Abu-Dayeh A: Kikuchi-Fujimoto disease following SARS-CoV2 vaccination: case report. *IDCases.* 2021, 25:e01253. 10.1016/j.idcr.2021.e01253
16. Tan HM, Hue SS, Wee A, See KC: Kikuchi-Fujimoto disease post COVID-19 vaccination: case report and review of literature. *Vaccines.* 2021, 9:1251. 10.3390/vaccines9111251
17. Guan Y, Xia X, Lu H: Kikuchi-Fujimoto disease following vaccination against COVID-19. *J Hematop.* 2022, 15:21-5. 10.1007/s12308-021-00477-1
18. Daghi S, Belmoutfif N, Rami A, Al Bouzidi A, Bouanani N: Kikuchi-Fujimoto Disease or histiocytic necrotizing lymphadenitis following mRNA COVID-19 vaccination: a rare case. *Cureus.* 2022, 14:e24155. 10.7759/cureus.24155
19. Piłchowska ME, Pinkus JL, Pinkus GS: Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease): lesional cells exhibit an immature dendritic cell phenotype. *Am J Clin Pathol.* 2009, 131:174-82. 10.1309/AJC7V1HJLO7KK
20. Pilieri SA, Facchetti F, Ascani S, et al.: Myeloperoxidase expression by histiocytes in Kikuchi’s and Kikuchi-like lymphadenopathy. *Am J Pathol.* 2001, 159:915-24. 10.1016/S0002-9440(10)61767-1